Opportunities & Solicitations

How Does This Work?

JPM-MCS offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s objective or sub-objective area. Active and Closed solicitations are listed below.


Only MCDC Members in good standing can submit whitepapers and proposals in response to solicitations. Please log-in to the MCDC Members Only Site to view complete solicitation information. If you do not have a username and password, please click here to request access.

If you are not a MCDC member and wish to become one, please click here for instructions.

Project Status
For Current Status of Each Sub-Objective Released to Date, click here

ACTIVE SOLICITATIONS
MCDC-RPP-18-03

February 9, 2018, the MCDC Consortium Management Firm released Request for Prototype Proposals MCDC-RPP-18-03 on the Members Only portion of the MCDC Website. This solicitation has been put forth by the Joint Science and Technology Office (JSTO), Defense Threat Reduction Agency (DTRA) through Joint Project Manager – Medical Countermeasure Systems (JPM-MCS). This solicitation is for the Treatment Objective area and contains two Sub-Objective areas:

PRE-18-06: Enhanced circulatory stability and GMP manufacturing of phosphotriesterase (PTE) / organophosphorus hydrolase (OPH) variants as prophylaxis against a broad-spectrum of organophosphorus nerve agents (OPNAs)
White Paper Due Date: February 28, 2018 at 12:00 PM NOON ET
Full Proposal Due Date: April 13, 2018 at 12:00 PM NOON ET

TRE-18-07: Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents
White Paper Due Date: February 28, 2018 at 12:00 PM NOON ET
Full Proposal Due Date: April 13, 2018 at 12:00 PM NOON ET

TRE-18-08: Proof of Concept Formulations for CBRN Medical Countermeasures to be administered via Autoinjector
White Paper Due Date: February 28, 2018 at 12:00 PM NOON ET
Full Proposal Due Date: April 13, 2018 at 12:00 PM NOON ET

Only MCDC Members in good standing can submit proposals in response to this solicitation. Proposals are due as indicated above. Submission instructions are included in the solicitation.

MCDC-RPP-18-02

Request for Prototype Proposals MCDC-RPP-18-02 was released January 10, 2018 and solicited White Papers followed by Full Proposals for the following Sub-Objectives topics within the Treatment Objective areas. These topics have been put forth by the Joint Project Manager – Medical Countermeasure Systems (JPM-MCS).

Only MCDC Members in good standing can submit White Papers and Full Proposals in response to this solicitation. The actual solicitation documents can be found on the MCDC Members Only site.

TRE-18-04: Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic Evaluations
TRE-18-05: Development of an FDA-approved medical countermeasure for treatment of multi-drug resistant bacterial biological warfare agents delivered by an aerosol route of exposure

Should you wish to consider membership in the MCDC, please contact us at MCDC@ati.org for more information.



INTENT TO ANNOUNCE

CLOSED SOLICITATIONS
MCDC-RPP-18-01 for JSTO (Released October 19, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required
DET-18-01:(WP/P) Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial Agent
DET18-02:(WP/P) Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology Approaches
TRE-18-03:(WP/P) Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents

MCDC-RPP-17-03 (released June 16, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required
PRE-17-06: (P) Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccine
DET-17-07: (WP/P) Man-Portable Diagnostics System (MPDS) – Expanded Scope
DET-17-08: (WP/P) Chemical Exposure In Vitro Diagnostics (IVD) (ChemDx)

MCDC-RPP-17-02 (released February 13, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARV

17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)

17-05: Man-Portable Diagnostics System (MPDS)

MCDC-RPP-17-01 (released January 17, 2017)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

TRE-17-01: (P) Development of Monoclonal Antibody and Related Technologies as Medical Countermeasures against aerosolized Venezuelan Equine Encephalitis (VEE) Virus
TRE-17-02: (WP/P) Development of Efficacious Antiviral Countermeasures

MCDC-RPP-16-02 (released July 15, 2016)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required
TRE-16-03: (WP/P) Development of a Dual Drug Delivery Device (D4) Autoinjector
PRE-16-04: (WP/P) Lyophilized Formulation and Final Product Manufacturing Process for Western, Eastern, and Venezuelan equine encephalitis (WEVEE) Vaccine
PRE-16-05: (WP/P) Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical Study
PRE-16-06: (WP/P) Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD)


MCDC-RPP-16-01 (released June 22, 2016)
Sub-objective areas: PRE = Prevention; DET = Detection; TRE = Treatment (WP/P) = White Paper and Full Proposal required; (P) = Full Proposal only required

PRE-16-01: (P) Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug Product
PRE-16-02: (P) Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and B